<DOC>
	<DOC>NCT01658449</DOC>
	<brief_summary>The purpose of this study is to compare the tolerability and acceptability of a formulation containing Hypertonic saline 7% (HS) alone and a formulation containing HS and Hyaluronic acid 0.1% in a population of Cystic Fibrosis (CF) patients who already showed poor tolerance to HS.</brief_summary>
	<brief_title>Comparison of the Tolerability of Two Formulations of Hypertonic Saline in Cystic Fibrosis Patients</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Hyaluronic Acid</mesh_term>
	<criteria>diagnosis of Cystic Fibrosis (genotyping and sweat test) &gt; 8 yearold clinically and therapeutically stable disease in the last 30 days; Forced Expiratory Volume in one second (FEV1) ≥ 50% of predicted value; intolerance (cough, throat irritation, saltiness) to previous administration of 5.8% hypertonic saline solution. decrease in FEV1 &gt;15% after first inhalation of hypertonic saline; Burkholderia cepacia infection; infective exacerbation requiring antibiotic treatment in the 15 days preceding enrolment; patient non compliant to standard therapy; Lung transplant; Patient unable to perform reproducible spirometry; Intolerance to β2 bronchodilators; Concurrent enrolment in other clinical trials; Plasmatic creatinine and transaminases more than twice the normal values.</criteria>
	<gender>All</gender>
	<minimum_age>8 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2009</verification_date>
</DOC>